Drug Trial Radar · NCT03373201
Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia
Last checked: Nov 19, 2026Latest source record: Sep 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
320
Actual
Start
Oct 16, 2017
Primary completion
Mar 5, 2018
Study completion Mar 5, 2018
Sponsor
- Lead sponsor
- Vanda PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Dec 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to investigate tasimelteon vs. placebo on sleep in healthy individuals after a phase advance in jet lag type insomnia.
Conditions
- Jet Lag Type Insomnia
Interventions
TasimelteonDrug
Oral capsule
PlaceboDrug
Oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Sleep Time in the First Two Thirds of the NightTime frame: 1 Day
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Vanda Investigational Site
Little Rock, Arkansas
Vanda Investigational Site
Alameda, California
Vanda Investigational Site
San Diego, California
Vanda Investigational Site
Santa Monica, California
Vanda Investigational Site
Oakland Park, Florida
Vanda Investigational Site
Atlanta, Georgia
Vanda Investigational Site
Chevy Chase, Maryland
Vanda Investigational Site
St Louis, Missouri
Vanda Investigational Site
New York, New York
Vanda Investigational Site
Cincinnati, Ohio
Vanda Investigational Site
Oklahoma City, Oklahoma
Vanda Investigational Site
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.